Pricing Sign in

NAMS

NewAmsterdam Pharmadistress 0/10 · well-funded / low risk

$30.62-3%today-26% from 52w high

newamsterdampharma.com100 employeesNaarden, NetherlandsBiotechnology

Lead: Lipidemia

Revenue

pre-revenue

Liquidity

$707M

Runway

5.0 yrs

Shares 1y

+4%

Price & events

-12.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

-3.4%

1D

-1.4%

1W

-2.5%

1M

-2.7%

3M

-8.1%

6M

+27.7%

1Y

+61.7%

2Y

+215.7%

5Y

+188.5%

All

Overview

Market Cap: $3.58B
Volume: 43.69K
52 Week Range: $20.92 – $41.45
Total Shares: 116.90M
Float Shares: 80.70M
Short %: 9.13%
% Held by Insiders: 0.91%
% Held by Institutions: 106.66%
RVOL: 0.04x
Beta: 0.08

Pipeline stages · 1 programs

obicetrapib 10 mg, ezetimibe 10 mg FDC daily

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-09

Pipeline · 5 trials · 5 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-09 Estimated 50% readout ~2026-10-16	Phase 2	Obicetrapib 10mg	Antioxidant Absorption	—	recruiting
2026-11 Estimated 50% readout ~2027-01-15	Phase 3	Obicetrapib	Atherosclerotic Cardiovascular Disease	—	active not recruiting
2026-11 Estimated 50% readout ~2026-12-16	Phase 2	obicetrapib 10 mg, obicetrapib/evolocumab 140 mg Q 2 weeks	Dyslipidemias	—	recruiting
2027-11 Estimated 50% readout ~2028-01-15	Phase 3	obicetrapib 10 mg, ezetimibe 10 mg FDC daily	Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic	—	active not recruiting
2028-03 Estimated 50% readout ~2028-05-15	Phase 3	obicetrapib 10 mg, ezetimibe 10 mg FDC daily	Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)	—	recruiting

Catalyst news & presentations · 11

2027Guided 40%readoutPhase 3obicetrapib · Phase 3 REMBRANDT trial completionSEC 8-K
2026Guided 40%trial initiationsecondaryobicetrapib · Initiate first dedicated Alzheimer's trialSEC 8-K
2H26Guided 55%chmp opinionCHMP (EU)obicetrapib; obicetrapib/ezetimibe FDC · EMA approval decisionSEC 8-K
2026Guided 40%enrollment completesecondaryPhase 3obicetrapib/ezetimibe FDC · Complete enrollment of REMBRANDT trial (~300 patients)SEC 8-K
year end 2026Guided 40%readoutPhase 3obicetrapib; obicetrapib/ezetimibe FDC · Topline results from RUBENS trialSEC 8-K
2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
fourth quarter of 2025trial initiationsecondaryPhase 3obicetrapib plus ezetimibe · initiate RUBENS Phase 3 trialSEC 8-K
second half of 2025regulatory submissionFiled (NDA/BLA)obicetrapib · EMA submission by partner MenariniSEC 8-K
throughout 2025conferencedata presentationsecondaryobicetrapib · Additional data from BROADWAY, TANDEM, BROOKLYNSEC 8-K
July 2025conferencedata presentationsecondaryPhase 3obicetrapib · Results to be presented at AAIC conference in July 2025.SEC 8-K
June 11, 2025conferencedata presentationsecondaryobicetrapib · R&D Day presenting update on obicetrapib programsSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 116,903,979 · 0 offerings/1y · 0 PIPEs

none

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

strong buy · target $50 (+62% upside) · 14 analysts

2026-06-30RBC CapitalOutperform
2026-02-19GuggenheimBuy
2026-02-18NeedhamBuy
2026-01-21RBC CapitalOutperform
2025-12-16StifelBuy
2025-12-02Goldman SachsNeutral

Competitors — Lipidemia

MRKMerck & Co., Inc.$318.8B · D3
ARWRARROWHEAD PHARMACEUTICALS, INC.$12.3B · D3
EDITEditas Medicine, Inc.$266M · D6
SLNCFSilence Therapeutics plc$213M · D5

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.